Published in Lancet Oncol on July 21, 2011
Exercise in Patients With Multiple Myeloma (EMMY) | NCT02439112
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Myeloma as a model for the process of metastasis: implications for therapy. Blood (2012) 1.36
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. Rev Bras Hematol Hemoter (2013) 0.98
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica (2015) 0.94
Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol (2014) 0.89
Prognostic factors for local control and survival in patients with spinal cord compression from myeloma. Strahlenther Onkol (2012) 0.87
Clinical role of bisphosphonate therapy. Int J Womens Health (2012) 0.85
Treatment of bone metastases before the onset of pain. Int J Clin Oncol (2012) 0.84
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model. PLoS One (2013) 0.80
Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol (2013) 0.79
Remarkable regression of an osteolytic lesion of large cell lung cancer treated with zoledronic Acid: a case report. Case Rep Oncol (2012) 0.79
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep (2015) 0.79
Bone cement augmentation procedures for spinal pathologic fractures by multiple myeloma. J Korean Med Sci (2014) 0.77
Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study. Biomed Res Int (2015) 0.75
Zoledronic acid for all patients with newly diagnosed multiple myeloma? Lancet Oncol (2011) 0.75
Novel therapeutic targets in myeloma bone disease. Br J Pharmacol (2014) 0.75
Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. Oncotarget (2017) 0.75
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). J Bone Miner Res (2017) 0.75
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem (2002) 2.14
Bisphosphonates: clinical experience. Oncologist (2004) 2.12
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
Bisphosphonates: preclinical review. Oncologist (2004) 2.08
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol (2008) 1.74
Analysis of repeated events. Stat Methods Med Res (2002) 1.73
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab (2010) 1.60
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol (2005) 1.56
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol (2007) 1.42
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone (2010) 1.40
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol (1998) 1.30
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol (2001) 1.19
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol (2010) 1.09
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol (2011) 0.99
Myeloma bone disease. Best Pract Res Clin Haematol (2005) 0.91
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 5.48
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med (2011) 5.16
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol (2006) 4.32
A memory retrieval-extinction procedure to prevent drug craving and relapse. Science (2012) 4.04
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res (2009) 3.70
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol (2008) 3.33
Validity of composite end points in clinical trials. BMJ (2005) 3.26
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Serum test for assessment of patients with Bence Jones myeloma. Lancet (2003) 3.04
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science (2010) 2.91
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation (2013) 2.73
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol (2008) 2.54
Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 2.51
Psychopathology among New York city public school children 6 months after September 11. Arch Gen Psychiatry (2005) 2.48
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med (2008) 2.44
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials (2005) 2.40
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood (2012) 2.39
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest (2008) 2.35
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood (2004) 2.31
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
ARL1, a LOB-domain protein required for adventitious root formation in rice. Plant J (2005) 2.24
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol (2011) 2.14
Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract (2013) 2.12
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood (2011) 2.12
OsPHR2 is involved in phosphate-starvation signaling and excessive phosphate accumulation in shoots of plants. Plant Physiol (2008) 2.06
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol (2010) 2.03
Design, analysis, and presentation of crossover trials. Trials (2009) 2.01
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99